Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

被引：7

作者：

Kotecki, N. ^{[1
]}

Champiat, S. ^{[2
]}

Delord, J-P. ^{[3
]}

Vinceneux, A. ^{[4
]}

Jungels, C. ^{[1
]}

Marabelle, A. ^{[2
]}

Korakis, I. ^{[3
]}

Wojciekowski, S. ^{[5
]}

Block, E. ^{[6
]}

Clarke, N. ^{[7
]}

Fromond, C. ^{[8
]}

Poirier, N. ^{[9
]}

Costantini, D. ^{[10
]}

Vasseur, B. ^{[11
]}

Cassier, P. A. ^{[4
]}

机构：

[1] Inst Jules Bordet, Med Oncol, Brussels, Belgium

[2] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France

[3] Inst Claudius Regaud, Dept Med Oncol, IUCT Oncopole, Toulouse, France

[4] Ctr Leon Berard, Med Oncol, Lyon, France

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Stat, Biberach, Germany

[6] Boehringer Ingelheim Pharmaceut Inc, Clin Dev, Ridgefield, CT USA

[7] Boehringer Ingelheim Pharma GmBH & Co KG, Translat Med & Clin Pharmacol, Ingelheim, Germany

[8] OSE Immunotherapeut, Preclin Dev & Translat Med, Paris, France

[9] OSE Immunotherapeut, Res Dept, Nantes, France

[10] OSE Immunotherapeut, Early Dev, Paris, France

[11] OSE Immunotherapeut, Immunooncol, Paris, France

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.1367

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

983P

引用

页码：S841 / S842

页数：2